Treat Cancer to Defeat Cancer

ACGT ALLIANCE FOR CANCER GENE THERAPY
Discovering new ways to treat and defeat cancer

2016
#acgtProgressReport
Alliance for Cancer Gene Therapy is the only charitable organization in the nation dedicated exclusively to funding and fostering research into cell and gene therapies for cancer.

Our mission is to seek out and support revolutionary scientific research into the causes, treatment and prevention of all types of cancer, using cells and genes as medicine.

To this end we fund and monitor studies and trials that meet the highest possible standards, educate the public on the potential for targeted medicine, and facilitate greater collaboration among the scientific and philanthropic communities to promote progress.
#acgtIntheNews

**Cancer Moonshot Takes Aim.**
Vice President Joseph Biden announced the start of a national public access medical database to centralize genomic and clinical data, opening with 12,000 patients from the National Cancer Institute. The initiative, funded through the NIH, aims to bring to market by 2020 more effective therapies for cancer.

**New York Times series reports on immunology breakthroughs.**
Citing long-term remissions for blood cancers, science reporters demystify the science and spotlight ACGT Fellows Dr. Carl June and Dr. Michel Sadelain for advances in the field.

**First Oncolytic Viral Therapy approved for Melanoma.**
The FDA approved Imlygic from Amgen, the first drug using a genetically modified virus to treat melanoma.

**Drug Giants Kite Pharma, Novartis & Juno Therapeutics** announced hope for approvals in the next year or so for immunotherapy treatments for various cancers.

**ACGT Fellows featured for revolutionary approach.** Dr. Meenakshi Hegde and Dr. Nabil Ahmed reported progress using an approach to destroy antigens that prevent treatment for glioblastoma, one of the more deadly brain cancers.

**Rally for Medical Research on Capitol Hill**
lobbied legislators to secure $2 billion more for medical research threatened by budget cuts.
#acgtGrantAwards

Young Investigator Awards fund $250,000 over three years for innovative laboratory research at a dedicated research institute.

Yvonne Yu-Hsuan Chen, MS, PhD  
*Assistant Professor, Chemical & Biomolecular Engineering, University of California, Los Angeles*

**Immunotherapy for Lymphoma/Leukemia.**  
Dr. Chen focuses on T-cell therapy using a patient’s own immune cells to attack cancer. Reprogrammed cells contain a synthetic protein that binds to disease markers to attack cancer cells. She studies patients who evidence a specific marker in lymphoma and leukemia that prevents a response to conventional therapies. She aims to refine the technique and develop a screening method for consistently high impact. Dr. Chen earned an MS and PhD in Chemical Engineering at the California Institute of Technology and held postdoctoral positions at Seattle Children’s Research Institute and Harvard Medical School.

Brent Hanks, MD, PhD  
*Assistant Professor, Duke University Medical Center*

**A Vaccine for Melanoma.** Melanoma has been steadily increasing and once spread, patients have less than a 10% prognosis for recovery. Dr. Hanks studies cancer pathways that block the immune system, particularly a fatty acid transporter that plays a crucial role. The hope is a vaccine to neutralize the barrier, so the body’s natural killer T-cells can destroy cancer cells. Dr. Hanks served as Fellow and Resident at Duke University Medical Center after earning an MD in Medicine and a PhD in Cancer Immunology at Baylor College of Medicine.
Samuel G. Katz, MD, PhD  
*Assistant Professor, Pathology, Yale University*

**Immunotherapy for Blood Cancers; Swim Across America Award.** Immunotherapy often relies on a dual-action protein known as a chimeric antigen receptor [CAR] to recognize a tumor as a threat. Dr. Katz’s study uses RNA to target blood cancer to maximize impact and minimize effect on healthy cells. Dr. Katz earned his MD in Medicine and a PhD in Genetics at Harvard Medical School, Division of Medical Sciences, served a residency and fellowship at Brigham and Women’s Hospital, and post-doctoral fellowship at Dana Farber Cancer Institute.

Crystal Mackall, MD  
*Professor, Pediatrics/Internal Medicine, Stanford University*

**Immunology for Osteosarcoma; The Wendy Walk-ACGT Sarcoma Grant.** Wendy Walk is a non-profit founded in 2010 by Wendy Landes’ children. The joint Clinical Investigator Award funds $500,000 over three years for translational research from the lab to clinical trial.

Osteosarcoma is a lethal bone cancer that attacks children. Dr. Mackall’s research uses a patient’s engineered T-cells to destroy cancer cells. She received her MD from Northeastern Ohio University and served a fellowship in pediatric hematology/oncology and a post-doctoral fellowship at the National Cancer Institute. She recently was Head of the Immunology Section and Chief of the Pediatric Oncology Branch at the NCI.

For a complete listing of ACGT grantees, visit www.acgtfoundation.org
At the forefront of cell and gene therapy is immunotherapy, also known as immune-mediated therapy or immunology. Because cancer is organic and because cancer cells are even more tenacious than normal cells in defending intervention, the immune system is inactive with cancers. Immunology aims to awaken the immune system to the threat and deactivate the inhibitors that block the invasion of killer T-cells.

“*This is a sea change – melanoma, kidney, lung, esophageal, bladder, liver, neck and head cancers all respond to immunotherapy.*”

– Dr. Michael Lotze, Member, ACGT Scientific Advisory Council, Lion Biotechnologies, Inc.

Immunology is a concept that has been around for many years, but advanced technology has made it possible for tremendous progress in just the last decade.

This approach to gene therapy is a noninvasive procedure: doctors extract a patient’s own cells then inject the cells back after re-engineering them in the laboratory. The immune system recognizes the threat and the cancer target is clearly marked.

CAR-T cell therapy has shown remarkable success treating B-cell hematologic malignancies such as forms of leukemia and lymphoma. The technique focuses on the receptors in T-cells that lock into protein fragments found on the surface of abnormal cells. In this way, modified T-cells attack the cancer and only the cancer, without the toxicity of traditional treatment. Results may range from 40-90% response within days or weeks. More funding for research and trials are needed with solid cancers.

The next challenge is to match the most effective treatment to each individual.
Also called OV or virotherapy, this treatment uses a virus to awaken the immune system. Viruses are harmless, once decoded, and there are over 3500 known viruses with the potential to be therapeutic agents.

Viruses spread rapidly within cancer cells and signal the immune system to attack the invader.

A simple concept, contemplated a century ago, but only possible now through the advances of genetic engineering and the mapping of the human genome.

In research, oncolytic viruses have an exemplary safety record. Just this year, virotherapy was successfully used to treat glioblastoma, a deadly brain cancer, as well as melanoma, blood, lung and colon cancers.

Researchers throughout the world are studying the distinctions between types of cancers to learn how to better use viruses to penetrate cancer cells and stimulate an immune response.

“Cancer patients who previously had no opportunity to survive are alive, particularly those with leukemia and melanoma, and some solid cancers.”

– Dr. John Bell, Member, ACGT Scientific Advisory Council, Ottawa Hospital Research Institute

Major pharmaceutical companies are looking closely at the potential for virotherapy drugs like Imlygic, an OV treatment approved for metastatic melanoma.

The challenge is to match the right virus to the cancer and to learn how to mass manufacture viral agents to treat large numbers of patients.
Clustered Regularly Interspaced Short Palindromic Repetition [CRISPR] is the talk of the medical science community. What is it? A fantastically precise tool for genetic editing.

The mapping of the human genome opened the door to revolutionary treatments and provides an opportunity to target a cancer treatment to match the genetic profile. CRISPR will allow us to make miniscule changes in the DNA that can stop cancer in its tracks.

The technique was revealed just three years ago by researchers using a DNA cut and paste with bacteria and viruses. They realized they could also edit human genes.

Once the cancerous cell is cut, it will repair itself or the body’s natural killer T-cells will take aim to destroy diseased cells. In effect, we will chisel cancer out of DNA.

The discipline is so new that scientists from around the world gathered this year in Washington, DC for the first international summit on human gene editing. They agreed on several principles not the least of which is not to use the tool for human genetic engineering. On the other hand, CRISPR is being used to stimulate cancers in laboratory animals, for the purpose of study.

CRISPR has the potential to battle all forms of disease as well as genetic disorders. The opportunities are limitless.

“The most exciting aspect of gene therapy is identifying the unique attributes of each patient, so we can better target the treatment and with fewer side effects.”

– Dr. Stephen Eck, Member, ACGT Scientific Advisory Council, Astellas Pharma, Inc.
John Walter named ACGT CEO/President. The former CEO of the Leukemia and Lymphoma Society, John dramatically expanded research collaborations between LLS and biotech and academia, and spearheaded record revenue growth. John previously worked with the March of Dimes, Donaldson, Lufkin & Jenrette, and Bristol-Myers Squibb. He succeeds Barbara Netter, who continues her leadership role as Honorary Chairman.

Scientific Symposium on Research Status and Challenges. ACGT Research Fellows, Board and Scientific Advisory Council Members, and special guests, focused on next steps for cell and gene therapies. All agreed that the research has broken treatment barriers and human trials have saved or extended lives. The challenge ahead is to refine therapeutic design and delivery systems, and match treatment to the cancer profile and to the individual.

Chau Q. Khuong Joins the Board of Directors. A partner at OrbiMed Advisors, a global health care investment firm, Chau has been an active lead investor in innovative drug development. He earned a BS in molecular, cellular and developmental biology, and an MPH, with a focus on infectious disease, at Yale University.

10th Annual Swim Across America Greenwich-Stamford Event a Great Success. The popular event on behalf of ACGT put total revenues over the decade at $3 million+. Funds raised this year continue to support three Swim Across America-ACGT grants for brain cancer, blood cancer and pediatric brain cancer treatments.
#acgtSupporters 2015-16

Thank you for your support. Every penny counts and every penny goes directly to research – a separate fund supports administrative expenses. Stay with us, we are SO close.

$50,000 +
Mr. and Mrs. Jeb Embree
Mr. and Mrs. Bill Fitzgerald
Mrs. Barbara Netter
Swim Across America
Wendy Walk/Alexandra Landes

$25,000 to $49,999
Davies Ward Phillips and Vineberg LLP
Mr. and Mrs. Alan Englander
Geneve Corporation
Mr. Peter Glicklich
Ms. Alva Greenberg
Mr. and Mrs. Peter Hearn
Reuben and Arlene Mark
Mr. and Mrs. John Sites
The Wasily Family Foundation

$10,000 to $24,999
Mr. Silas Chou
The Cogan Family Foundation
Mr. and Mrs. David Darst
Ms. Joanna Karatzas
Frances Brody Foundation
Drs. Aya and Eddy Jakobovits
Mr. Jeffrey Keil
Dr. and Mrs. John Lahey
Mr. and Mrs. Shau-Wai Lam
Gen Re
Duff & Phelps
Sharon and Barnet Phillips
Quinnipiac University
Mr. and Mrs. John Rosenwald

$5,000 to $9,999
Alvarez and Marsal Holdings, LLC
Arnhold Foundation
CIGNA
Mr. Donald Drelich
Eugene and Emily Grant Family Foundation
Alice Kaplan and Jason Aronson
Mr. and Mrs. Edward Lampert
The Lapin Foundation
The Ernest and Joan Liu Foundation
Marx-Better Foundation
Mr. John Miller
Mr. and Mrs. Toby Ritter
Mr. Tom Tryforos

$1,000 to $4,999
Mr. Steven C. Annus
Ms. Elizabeth Armstrong
Mr. and Mrs. Grant Behrman
Mr. William R. Berkley
Mr. and Mrs. Allan Bernard
Mr. Arthur R. Brill
Mr. Anthony Capozza
James and Victoria Chang Family Foundation
Mr. and Mrs. Sumi Chang
Daniel Cloud Trust
Mr. Stephen Corman
Mr. James Davidson
Lucy and Nat Day
Mr. Martin Dickman
Mr. and Mrs. Dean Duffy
Mrs. Nancy A. Duffy
Ms. Pamela Duke
Mr. and Mrs. Bernard Eichwald
Arline and Paul Gardner
Ms. Pam Goergen
Nancy and Robert Gregory
H.H. Brown Shoe Company
John P. Hanson, Jr. M.D.
Mr. Richard Horowitz
Carol Johnson and Steve Scott
Danielle Katsaros
Ms. Carol A. Klimek
Mr. and Mrs. Andrew Kramer
Mr. and Mrs. Robert M. Leopold
Susan and Bob Levis
Ms. Karen Li
Ms. Connie Lieber
Joyce and Larry Light
Mr. and Mrs. Brian Lindquist
Ms. Rachel Lipari
Mr. Theodore Lobsenz
Mr. Leif Luglan
Mr. James Mack
Mr. Richard Malnight
Mr. Richard Margenot
The Mount Sinai School of Medicine
Mr. and Mrs. Alfred Netter
The Perkins Family Foundation
Ms. Leigh H. Perkins
Mr. and Mrs. Richard Radcliffe
Mr. David Raizen
Mr. Roy R. Raizen
The Scrivan Family Foundation
Jill and Robert Serling Families
Mr. Robert Shasha
Elizabeth and David Sherman
Mr. and Mrs. Richard Silver
Mr. LeRoy Sluder III

Mrs. Sarah H. Thomas and Mr. H. William Smith
Dr. Kathleen Van Cleef-Toedt
Mr. Peter Trent
University of Massachusetts Medical School
Mr. Austin James Warrin
Mr. and Mrs. Mark Weinstein

Under $ 1,000
Ms. Barbara Abramson
Mr. Richard Allen
Mr. Mark Azzopardi
Mr. and Mrs. Lionel Bandler
Mrs. Lucy R. Banker
Mr. Stanley Barauskas
Mr. and Mrs. Gilbert Bassin
Ms. Claudia M. Beard
Mr. and Mrs. John Bennett
Mr. and Mrs. Andre Block
Mr. and Mrs. Charles Block
Ms. Deborah Block
Ms. Diana Block
Mr. and Mrs. Farhad Bokhour
Mr. and Mrs. Charles Boorady
Mr. and Mrs. Harry Bower
Mr. Jeremy Bradshaw
Hugh and Carmen Bridgford
Mr. Brian Brown
Bruce Museum of Arts and Sciences
The Randy Cappiello Foundation, Inc.
Mrs. Joanne Delle Cave
Mr. and Mrs. John D. Chalk III
Mr. and Mrs. Robert Chandler
Mr. Joseph Cianci
Margaret and Jeff Cianci
Mrs. Stephanie Cohen
Ms. Deanna Congileo
Mr. and Mrs. Peter Crumbine
CSL Behring
Mr. Rob Cubbon
Angela and Vincent Cusumano
Mrs. Sandra DePompa
Venkat Dinavahi
Ms. Maureen Downie
Ivy and Marc Duneier
Mr. Eugene Eanes
Mr. Michael Englander
Mr. and Mrs. Joseph Fahys
Ms. Rosalind Fendon
Dr. and Mrs. Robert S. Fields
Mr. and Mrs. Arlen Fleisher
Mr. and Mrs. James Fogarty
Ms. Tara Framer
Mr. and Mrs. Ronald Friedman
B. Fuchs
Mr. John R. Fusek
Ms. Kathryn Gabler
Mr. Richard Gendelman
Mrs. Anne Gilhuly
Ms. Deanna Gilman
Mrs. Alexandra Gladstone
Arline and Richy Diamant Gold
Mr. and Mrs. Carl A. Goldman
Ms. Florence Goldstein
Mr. John Griswold
Mr. David Grossman
Mr. Leo Guthart
Reva and Jesse Halperin
Mr. Ira and Dr. Sandra Harkavy
Mr. and Mrs. William Hart Jr.
John and Kelly Hartman Foundation
Ms. Barbara R. Hayes
Ms. Mary Ellen Hayes
Dr. Andreas Henke
Ms. Kellie Hepler
Ms. Christine Herman
Mr. and Mrs. Thomas Hughes
Mrs. Kareen Jacobs
Mr. Walter Jenkins
Mr. H. Steven Kanofsky
Mr. and Mrs. Stuart Kaplan
Mr. and Mrs. John Kelly
Mr. Thomas Kerrigan
Ms. Maryln Kimmel
Mr. and Mrs. Erwin Kirsch
Ms. Lysa Randolf Kraft
Mr. Joseph A. Lander
Ms. Sondra C. Landy
Mr. Patrick LaPella
Linda and Irwin Lefkowitz
Jodi and Kenneth Levine
Mr. Martrevus De-Vaughn Lewis
Carolyn and James Lockhart
Mr. Gordon Mackenzie
Ms. Joanne Marien
Ms. Sheila Martin
Mr. and Mrs. James Mendler
Mr. Scott Mercer
Mr. and Mrs. Juan Meyer
Mr. Steve Milbauer
Mr. and Mrs. Clifford Millian
Mr. Paul Mylander
Mr. Stanley Newmark
Ms. Elizabeth Norris
Mr. Denis O’Brien
Mr. and Mrs. Peter O’Brien
Mr. Ron Ongaro
Lori and Robert Osborne
Ms. Dianne Ostroski
Mr. Ken Parmalee
Ms. Kathryn Payne
Mrs. Valerie Perry
Mr. and Mrs. Myron Picoult
Mr. Wynn Plaut
Mr. William Pritz
Ilse and Paul Puri
Ms. Barbara L. Puszertz
Mr. and Mrs. James Read
Mr. Michael Reeves
Mr. John Reinsberg
Ms. Lorraine N Reiss
Mr. Randy Ress
Mr. and Mrs. Charles Rich
Mr. Stephen Rippon
Ms. Deborah Rivers
Mr. Leandro P. Rizzuto
Ms. Ann Robb
Mrs. Francine Roberson
Mrs. Erin Rogol
Mr. and Mrs. Victor Romley
Mildred Rosenberg
Sheri and James Rosenfeld
Sandra and Dennis Rosenzweig
Pam and Bert Rowley
Mr. Hubert Emile Ruel
Mr. Wilbert Ruffner
Mr. and Mrs. Richard Rupp
Faith and Philip Ruppel
Nancy and Stephen Sahlein
Mr. Peruvemba Satish
Mr. Robert Schermer
Mr. and Mrs. Brian R. Schlier
Phyllis and Jay Schondorf
Ms. Louise Schreiber
Ms. Heather Schrum
Pat and Joe Schubert
Mr. and Mrs. Louis Senatore
Mr. and Mrs. Bobeck Shayegani
Mr. Jerry Shields
Hope and Harold Simkowitz
Mr. and Mrs. Laurence Simon
Anne and Ronald Simon
Mr. and Mrs. Robert Slatkin
Ms. Alice J. Smith
Mr. and Mrs. Thomas Spellane
Ms. Lauren Spicehandler
Mrs. Marilyn Stein
Ms. Nancy Stillerman
Ms. Debra Stone
Ms. Barbara Burke Southerland
Mr. and Mrs. Markley Suthers
Mr. and Mrs. C. Winfield Swarr
Donna and Scott Tagliarino
Ms. Julie Thiele and
Mr. Paul Kempner
Mr. Allen L. Thomas
Ms. Virginia D. Thomas
Karen and Doug Thomson
Dr. Deborah and The Honorable Richard Tolchin
Mr. and Mrs. Paul Toretta
Ms. Kirsten Trandem
Mr. David Treaster
Ms. Yvonne D. Tropp
Mr. Charles Tucker
Mr. and Mrs. Cris Tuft
Mr. and Mrs. Charles Tusa
Mr. and Mrs. Kevin Tyburski
Mr. Robert A. Van Cleef
Mr. and Mrs. Dennis van de Hey
Mrs. Pamela Van Hoven Clark
Mr. Karl Von Batsch
Mr. and Mrs. Matt Vossler
Mr. Thomas Walmsley
Mr. Raymond Walter
Ms. Judith E. Weber
Mrs. John Weinberg
Richard and Mary Weinstock
Mr. and Mrs. Lawrence Weiss
Corinne and Scott Welsh
Ms. Connie Burnett-West
Mr. and Mrs. John Williams
Ms. Eleanor Anne Wilson
Mr. and Mrs. Douglas Wink
Mr. Jordan Yarett
Cynthia and William Yeo
Carol and Donald Young

We have made every effort to ensure the accuracy of our donor listings. If your name has been omitted or misprinted, please accept our sincere apologies and notify us by email at jsmith@acgtfoundation.org or call Jill Smith at 203.358.5055
## Financial Report

Fiscal years ended April 2015 and 2016

### Condensed Statements of Activities

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support and revenue:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$950,413</td>
<td>$960,174</td>
</tr>
<tr>
<td>Contributions for administrative expenses (specially designated)</td>
<td>313,443</td>
<td>364,150</td>
</tr>
<tr>
<td>Contributed services</td>
<td>461,802</td>
<td>357,585</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>101,788</td>
<td>102,399</td>
</tr>
<tr>
<td>Realized and unrealized gains on investments, net</td>
<td>(362,703)</td>
<td>160,067</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT AND REVENUE</strong></td>
<td>1,464,743</td>
<td>1,944,375</td>
</tr>
<tr>
<td><strong>Expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>1,626,508</td>
<td>1,739,756</td>
</tr>
<tr>
<td>Management and general</td>
<td>219,584</td>
<td>225,863</td>
</tr>
<tr>
<td>Fundraising</td>
<td>154,222</td>
<td>103,799</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>2,000,314</td>
<td>2,069,418</td>
</tr>
<tr>
<td><strong>(Decrease) increase in total net assets</strong></td>
<td>(535,571)</td>
<td>(125,043)</td>
</tr>
<tr>
<td>Total net assets at beginning of year</td>
<td>3,857,659</td>
<td>3,982,702</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS AT END OF YEAR</strong></td>
<td>$3,322,088</td>
<td>$3,857,659</td>
</tr>
</tbody>
</table>

### Condensed Statements of Financial Position

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,259,779</td>
<td>$646,150</td>
</tr>
<tr>
<td>Contributions receivable, net</td>
<td>3,861,376</td>
<td>4,361,280</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>10,633</td>
<td>24,523</td>
</tr>
<tr>
<td>Accounts receivable and prepaid expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$5,131,788</td>
<td>$5,031,953</td>
</tr>
<tr>
<td><strong>Liabilities and net assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants payable</td>
<td>$56,401</td>
<td>$35,041</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>1,753,299</td>
<td>1,139,253</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>1,809,700</td>
<td>1,174,294</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>3,322,088</td>
<td>3,857,659</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$5,131,788</td>
<td>$5,031,953</td>
</tr>
</tbody>
</table>

Alliance for Cancer Gene Therapy, Inc.’s complete financial statements are available upon request.
“Right now, we are extending lives using cell and gene therapies as an adjunct to chemotherapy, and soon, based on new research, clinical trials and advanced technology, these therapies will take the lead and save lives.”

– Dr. Joseph Glorioso, University of Pittsburgh
<table>
<thead>
<tr>
<th>#acgtBoardofDirectors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Barbara Netter, MS</strong></td>
</tr>
<tr>
<td>Honorary Chairman and Co-Founder</td>
</tr>
<tr>
<td>Psychotherapist</td>
</tr>
<tr>
<td><strong>David Darst</strong></td>
</tr>
<tr>
<td>RGENIX</td>
</tr>
<tr>
<td><strong>Peter Glicklich</strong></td>
</tr>
<tr>
<td>Davies, Ward, Phillips and Vineberg</td>
</tr>
<tr>
<td><strong>Peter Hearn</strong></td>
</tr>
<tr>
<td>Guy Carpenter and Co.</td>
</tr>
<tr>
<td><strong>Tracy Holton</strong></td>
</tr>
<tr>
<td>Attorney</td>
</tr>
<tr>
<td><strong>Aya Jakobovits, PhD</strong></td>
</tr>
<tr>
<td>Adicet Bio</td>
</tr>
<tr>
<td><strong>Jeff Keil</strong></td>
</tr>
<tr>
<td>Chairman, Executive Committee</td>
</tr>
<tr>
<td>Knight Vinke</td>
</tr>
<tr>
<td><strong>Chau Khuong</strong></td>
</tr>
<tr>
<td>Orbimed Advisors</td>
</tr>
<tr>
<td><strong>John Lahey</strong></td>
</tr>
<tr>
<td>Quinnipiac University</td>
</tr>
<tr>
<td><strong>Alexandra Landes</strong></td>
</tr>
<tr>
<td>Wendy Walk</td>
</tr>
<tr>
<td><strong>Sharon Phillips</strong></td>
</tr>
<tr>
<td>Not-for-profit Consultant</td>
</tr>
<tr>
<td><strong>John Reinsberg</strong></td>
</tr>
<tr>
<td>Lazard Asset Management</td>
</tr>
<tr>
<td><strong>John Sites</strong></td>
</tr>
<tr>
<td>Wexford Capital</td>
</tr>
<tr>
<td><strong>Martin Winter</strong></td>
</tr>
<tr>
<td>Alvarez &amp; Marsal</td>
</tr>
<tr>
<td><strong>Martha Zoubek</strong></td>
</tr>
<tr>
<td>Wrightson-Ramsing Foundation</td>
</tr>
<tr>
<td><strong>Edward Netter</strong></td>
</tr>
<tr>
<td>(In Memoriam)</td>
</tr>
<tr>
<td>Founding President (2001-2011)</td>
</tr>
<tr>
<td><strong>John Walter</strong></td>
</tr>
<tr>
<td>CEO/President</td>
</tr>
<tr>
<td><strong>Margaret Cianci</strong></td>
</tr>
<tr>
<td>Executive Director</td>
</tr>
</tbody>
</table>